Skip to main content
Clinical Trials/NCT00840918
NCT00840918
Terminated
Not Applicable

The Effect of Perioperative Intravenous Lidocaine on Postoperative Outcomes After Cardiac Surgery

The Cleveland Clinic1 site in 1 country123 target enrollmentFebruary 2009

Overview

Phase
Not Applicable
Intervention
Lidocaine
Conditions
Atrial Fibrillation
Sponsor
The Cleveland Clinic
Enrollment
123
Locations
1
Primary Endpoint
atrial fibrillation
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

This study is being done to determine if lidocaine, administered during surgery and for 24 hours after surgery can reduce inflammation, thereby reducing the risk of atrial fibrillation and 30 day mortality after surgery. Participants undergoing cardiac surgery will be randomized to receive either lidocaine or placebo.

Detailed Description

Subjects undergoing cardiac surgery are randomized into one of two groups. * Group 1: Intravenous Lidocaine Group * Group 2: Intravenous placebo Group Either Lidocaine or placebo is administered throughout surgery and 24 hours after surgery. Patients in both groups will undergo quality of life assessments and functional recovery assessments post-surgery.

Registry
clinicaltrials.gov
Start Date
February 2009
End Date
December 15, 2014
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18-90 years old
  • Scheduled for cardiac surgery requiring cardiopulmonary bypass
  • Written informed consent

Exclusion Criteria

  • Off-pump surgical procedures
  • Anticipated deep hypothermic circulatory arrest
  • Any contraindications to the proposed interventions including lidocaine allergy
  • History of preoperative atrial fibrillation
  • Baseline Screening revealing preexisting dementia or delirium
  • Preoperative liver failure defined as Child-Pugh Score \> 6

Arms & Interventions

1

Intravenous Lidocaine group

Intervention: Lidocaine

Placebo

Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery

Intervention: Placebo

Outcomes

Primary Outcomes

atrial fibrillation

Time Frame: postoperatively

To test the hypothesis that lidocaine infusion started at induction of anesthesia and maintained for 24 hours postoperatively will decrease the incidence of atrial fibrillation compared to an intravenous saline control.

mortality

Time Frame: 30 days post surgery

To test the hypothesis that lidocaine infusion started at induction of anesthesia and maintained for 24 hours postoperatively will decrease the incidence of 30 day mortality as compared to an intravenous saline control.

Study Sites (1)

Loading locations...

Similar Trials